ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary products that activate the immune system of cancer patients to recognize and eradicate tumors. The Company's robust pipeline includes validated product candidates aimed at treating a variety of cancers in combination with standard of care and emerging immunotherapies.